Trump Administration Secures Rare Drug Pricing Deals With Eli Lilly and Novo Nordisk

The Trump administration has struck price-cutting deals with two major drugmakers for their popular weight-loss medications. Eli Lilly & Co. and Novo Nordisk A/S will lower costs in exchange for tariff relief and expanded Medicare coverage. The move marks a rare agreement of this kind in recent years.

Under the new arrangement, both companies will reduce prices on their widely used weight-loss treatments. In return, the US government will ease tariffs on their products and allow broader access for Medicare beneficiaries. These concessions aim to make the drugs more affordable for patients relying on federal healthcare programmes.

No other American or foreign pharmaceutical firms have secured similar pricing agreements with the US government over the past five years. Data from 2021 to 2026 shows no comparable negotiations or partnerships involving drugmakers and federal authorities. This makes the Eli Lilly and Novo Nordisk deals unusual in the current healthcare landscape.

The agreement will see lower costs for patients while granting the two companies financial incentives. Medicare recipients will gain improved access to the medications. The deal also highlights a shift in how the government negotiates drug pricing with major pharmaceutical firms.